Half-year report · HY
286A.TEDINET S100YWR5
Period2026-01-01 → 2026-06-30
Filed2026-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥13.7bn | 2026-01-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥24.7bn | 2025-01-01 → 2025-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.5bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Operating income | ¥395m | 2026-01-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | ¥1.1bn | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | ¥361m | 2026-01-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.1bn | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥981m | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥256m | 2026-01-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.2bn | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥489m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.8bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥824m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥560m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | ¥887m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥67.5bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥65.1bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥61.2bn | at 2025-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥45.2bn | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥43.3bn | at 2025-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥22.3bn | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥21.8bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥19.7bn | at 2025-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥11.0bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.1bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.9bn | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.1bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.2bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.1bn | at 2024-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥551m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.9bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.6bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥92m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.3bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.2bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.8bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥856m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥13.67 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥78.07 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.2 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥13.57 | 2026-01-01 → 2026-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥76.75 | 2025-01-01 → 2025-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.75 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 31.2% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.5% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.3% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 50
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2026-01-01 → 2026-06-30 | ¥376m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2026-01-01 → 2026-06-30 | ¥376m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2026-01-01 → 2026-06-30 | ¥118m |
| Reconciling Itemsreconciling | revenue | 2026-01-01 → 2026-06-30 | −¥16m |
| Reconciling Itemsreconciling | revenue intersegment | 2026-01-01 → 2026-06-30 | −¥16m |
| Reconciling Itemsreconciling | segment profit | 2026-01-01 → 2026-06-30 | −¥731m |
| Comprehensive Medical Management Support Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥5.1bn |
| Comprehensive Medical Management Support Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥5.0bn |
| Comprehensive Medical Management Support Businessreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥15m |
| Comprehensive Medical Management Support Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥457m |
| Elderly Care Related Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥4.4bn |
| Elderly Care Related Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥4.4bn |
| Elderly Care Related Businessreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥740,000 |
| Elderly Care Related Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥312m |
| Specially Controlled Medical Device Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥3.8bn |
| Specially Controlled Medical Device Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥3.8bn |
| Specially Controlled Medical Device Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥240m |
| —segment total | revenue | 2026-01-01 → 2026-06-30 | ¥13.3bn |
| —segment total | revenue external | 2026-01-01 → 2026-06-30 | ¥13.3bn |
| —segment total | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥16m |
| —segment total | segment profit | 2026-01-01 → 2026-06-30 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2026-01-01 → 2026-06-30 | ¥13.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2026-01-01 → 2026-06-30 | ¥13.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥16m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2026-01-01 → 2026-06-30 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-01-01 → 2025-06-30 | ¥219m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥219m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-01-01 → 2025-06-30 | ¥41m |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥640,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥640,000 |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥670m |
| Comprehensive Medical Management Support Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥3.1bn |
| Comprehensive Medical Management Support Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥3.1bn |
| Comprehensive Medical Management Support Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥395,000 |
| Comprehensive Medical Management Support Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥1.3bn |
| Elderly Care Related Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥3.7bn |
| Elderly Care Related Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥3.7bn |
| Elderly Care Related Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥245,000 |
| Elderly Care Related Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥187m |
| Specially Controlled Medical Device Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥3.6bn |
| Specially Controlled Medical Device Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥3.6bn |
| Specially Controlled Medical Device Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥276m |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥10.3bn |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥10.3bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥640,000 |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥10.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥10.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥640,000 |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | ¥1.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 552
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of treasury stock fin cf | Prior1InterimDuration | － | JPY |
| Purchase of treasury stock fin cf | InterimDuration | -22082000 | JPY |
| Proceeds from sales of treasury stock fin cf | Prior1InterimDuration | 122073000 | JPY |
| Proceeds from sales of treasury stock fin cf | InterimDuration | 42451000 | JPY |
| Decrease increase in deposit paid for repurchase of treasury stock fin cf | Prior1InterimDuration | － | JPY |
| Decrease increase in deposit paid for repurchase of treasury stock fin cf | InterimDuration | -777918000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1InterimDuration | -44704000 | JPY |
| Dividends paid to non controlling interests fin cf | InterimDuration | -42218000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | 856148000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | 1242724000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | -14117000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | -1632000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -3214914000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | 1884234000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 11139798000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 9052916000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | Prior1InterimDuration | 244227000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | InterimDuration | － | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 8169112000 | JPY |
| Cash and cash equivalents | InterimInstant | 10937151000 | JPY |
| Salaries and allowances sga | Prior1InterimDuration | 1129573000 | JPY |
| Salaries and allowances sga | InterimDuration | 1578253000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 173478000 | JPY |
| Provision for bonuses sga | InterimDuration | 223754000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 98521000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 110426000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1InterimDuration | 107000 | JPY |
| Provision of allowance for doubtful accounts sga | InterimDuration | 863000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E12328-000ComprehensiveMedicalManagementSupportBusinessReportableSegmentMember | 3059247000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E12328-000ElderlyCareRelatedBusinessReportableSegmentMember | 3690749000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E12328-000SpeciallyControlledMedicalDeviceBusinessReportableSegmentMember | 3551502000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 10301499000 | JPY |
| Revenues from external customers | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 219469000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 10520969000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 10520969000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E12328-000ComprehensiveMedicalManagementSupportBusinessReportableSegmentMember | 395000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E12328-000ElderlyCareRelatedBusinessReportableSegmentMember | 245000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E12328-000SpeciallyControlledMedicalDeviceBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 640000 | JPY |
| Transactions with other segments | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 640000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -640000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E12328-000ComprehensiveMedicalManagementSupportBusinessReportableSegmentMember | 3059643000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E12328-000ElderlyCareRelatedBusinessReportableSegmentMember | 3690994000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E12328-000SpeciallyControlledMedicalDeviceBusinessReportableSegmentMember | 3551502000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 10302140000 | JPY |
| Net sales | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 219469000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 10521610000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |